Nachum Vaisman1, Eva Niv, Yelena Izkhakov. 1. The Clinical Nutrition Unit, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel. vaisman@tasmc.health.gov.il
Abstract
BACKGROUND: It was suggested that acute ingestion of small amounts of fructose can improve glucose homeostasis. AIM: To study the effect of a long-term tri-daily supplementation of catalytic amounts of fructose on glucose tolerance of subjects with type 2 diabetes (NIDDM). METHODS: A double-blind, placebo-controlled study. Twenty-six subjects with uncontrolled NIDDM as indicated by high levels of hemoglobin A1C (Hgb(A1c)) and 2-h postprandial glucose levels >200 mg% were assigned to eitherfructose or maltodextrin supplementation (7.5 g) tri-daily after each main meal. The subjects were challenged with a fixed meal and blood was drawn for determining levels of glucose, insulin and triglycerides before and 2 h after meal at baseline and 1 month after study entry. Blood was drawn for total cholesterol, high-density and low-density lipoprotein cholesterol (LDL-c), fructosamine and Hgb(A1C) before study entry and at 1, 2 and 3 months into the study. RESULTS: No changes were observed in the difference between postprandial and pre-meal glucose, insulin or triglyceride levels in each group or between groups. No significant statistical differences were found in weight, total cholesterol, LDL-c and high-density lipoprotein cholesterol (HDL-c) in each group or between groups along the study period. After 1 month fructosamin levels decreased in the fructose-supplemented group but not in the maltodextrin-supplemented group (P<0.052). Hgb(A1C) levels decreased with time in both groups but were significantly lower at 2 months in the fructose group as compared to the maltodextrin group (P<0.03). CONCLUSIONS: Subjects with NIDDM may benefit from daily supplementation of catalytic amounts of fructose in their diet.
RCT Entities:
BACKGROUND: It was suggested that acute ingestion of small amounts of fructose can improve glucose homeostasis. AIM: To study the effect of a long-term tri-daily supplementation of catalytic amounts of fructose on glucose tolerance of subjects with type 2 diabetes (NIDDM). METHODS: A double-blind, placebo-controlled study. Twenty-six subjects with uncontrolled NIDDM as indicated by high levels of hemoglobin A1C (Hgb(A1c)) and 2-h postprandial glucose levels >200 mg% were assigned to either fructose or maltodextrin supplementation (7.5 g) tri-daily after each main meal. The subjects were challenged with a fixed meal and blood was drawn for determining levels of glucose, insulin and triglycerides before and 2 h after meal at baseline and 1 month after study entry. Blood was drawn for total cholesterol, high-density and low-density lipoprotein cholesterol (LDL-c), fructosamine and Hgb(A1C) before study entry and at 1, 2 and 3 months into the study. RESULTS: No changes were observed in the difference between postprandial and pre-meal glucose, insulin or triglyceride levels in each group or between groups. No significant statistical differences were found in weight, total cholesterol, LDL-c and high-density lipoprotein cholesterol (HDL-c) in each group or between groups along the study period. After 1 month fructosamin levels decreased in the fructose-supplemented group but not in the maltodextrin-supplemented group (P<0.052). Hgb(A1C) levels decreased with time in both groups but were significantly lower at 2 months in the fructose group as compared to the maltodextrin group (P<0.03). CONCLUSIONS: Subjects with NIDDM may benefit from daily supplementation of catalytic amounts of fructose in their diet.
Authors: D J A Jenkins; K Srichaikul; C W C Kendall; J L Sievenpiper; S Abdulnour; A Mirrahimi; C Meneses; S Nishi; X He; S Lee; Y T So; A Esfahani; S Mitchell; T L Parker; E Vidgen; R G Josse; L A Leiter Journal: Diabetologia Date: 2010-10-27 Impact factor: 10.122
Authors: John L Sievenpiper; Laura Chiavaroli; Russell J de Souza; Arash Mirrahimi; Adrian I Cozma; Vanessa Ha; D David Wang; Matthew E Yu; Amanda J Carleton; Joseph Beyene; Marco Di Buono; Alexandra L Jenkins; Lawrence A Leiter; Thomas M S Wolever; Cyril W C Kendall; David J A Jenkins Journal: Br J Nutr Date: 2012-02-21 Impact factor: 3.718
Authors: Adrian I Cozma; John L Sievenpiper; Russell J de Souza; Laura Chiavaroli; Vanessa Ha; D David Wang; Arash Mirrahimi; Matt E Yu; Amanda J Carleton; Marco Di Buono; Alexandra L Jenkins; Lawrence A Leiter; Thomas M S Wolever; Joseph Beyene; Cyril W C Kendall; David J A Jenkins Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Vivian L Choo; Effie Viguiliouk; Sonia Blanco Mejia; Adrian I Cozma; Tauseef A Khan; Vanessa Ha; Thomas M S Wolever; Lawrence A Leiter; Vladimir Vuksan; Cyril W C Kendall; Russell J de Souza; David J A Jenkins; John L Sievenpiper Journal: BMJ Date: 2018-11-21
Authors: Jarvis C Noronha; Catherine R Braunstein; Sonia Blanco Mejia; Tauseef A Khan; Cyril W C Kendall; Thomas M S Wolever; Lawrence A Leiter; John L Sievenpiper Journal: Nutrients Date: 2018-11-20 Impact factor: 5.717